{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-25-000062","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.923125+00:00","generated_at":"2026-05-17T17:19:14.996677+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vistagen reports Q1 net loss of $15.1M; fasedienol Phase 3 data expected Q4 2025 and H1 2026","bullets":["Net loss $15.1M for fiscal Q1 ended June 30, 2025, vs $10.7M a year ago; R&D expense up to $11.7M.","Cash, cash equivalents, and marketable securities at $63.2M as of June 30, 2025.","Topline data from PALISADE-3 Phase 3 trial of fasedienol (SAD) expected Q4 2025; PALISADE-4 data H1 2026.","PH80 for menopausal hot flashes – IND preparation underway for further Phase 2 development.","Appointed Elissa Cote as Chief Corporate Development Officer in June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-25-000062","json":"https://secwatch.observer/filing/0001411685-25-000062.json","markdown":"https://secwatch.observer/filing/0001411685-25-000062.md","text":"https://secwatch.observer/filing/0001411685-25-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000062/0001411685-25-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000062/vtgn-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:19:14.996677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}